Good news but nothing that is going to move the stock as there are still financial issues that have this company trapped for a while. More pain and no gain AMBS. But that's what is par for the course for this mismanaged company.

On a side note, I wonder if Lonza will end up getting back into bed with ESS by partnering with AMBS once trials show success. It would make sense for them from my vantage point.